{"id":"W2983242644","doi":"10.1093/neuonc/noz175.055","title":"ACTR-12. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE GLIOBLASTOMA IN THE RECURRENT AND ADJUVANT SETTING","year":2019,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Delmar (Canada)","funders":"","keywords":"Temozolomide; Bevacizumab; Medicine; Internal medicine; Oncology; Phases of clinical research; Adverse effect; Adjuvant; Methyltransferase; Radiation therapy; Clinical endpoint; Adjuvant therapy; Clinical trial; Cancer; Chemotherapy; Biology; DNA","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001328903,0.001334462,0.001618824,0.0003435038,0.0002895805,0.000605406,0.0005709515,0.0008450678,0.001965777],"category_scores_gemma":[0.0005153615,0.0004847779,0.001032022,0.000340846,0.0006482805,0.0004274486,0.0002253551,0.002241541,0.000713],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007518012,"about_ca_system_score_gemma":0.001100171,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001662251,"about_ca_topic_score_gemma":0.003492372,"domain_scores_codex":[0.9996452,0.0001703448,0.00001592409,0.00006315671,0.00003490546,0.00007034388],"domain_scores_gemma":[0.9995888,0.00004456296,0.00006304831,0.00003312393,0.00002841588,0.0002421882],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7416058,0.08620175,0.01218379,0.0004972563,0.001385047,0.0003624948,0.0002931631,0.002674775,0.07180503,0.0002318377,0.003573312,0.07918575],"study_design_scores_gemma":[0.3067347,0.6634237,0.02169708,0.00002020131,0.0005250789,0.000263854,0.00005102396,0.001482969,0.00386171,0.0001124001,0.001795569,0.00003176224],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996429,0.0008937026,0.0002854167,0.0001459977,0.00006182957,0.0008760041,0.0005041848,0.00007600975,0.0007277806],"genre_scores_gemma":[0.992995,0.0008247835,0.0009052014,0.0004769349,0.0001101016,0.001262026,0.001745198,0.00002029436,0.00166056],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001965777,"threshold_uncertainty_score":0.007027984,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01045461208059752,"score_gpt":0.2936011169252499,"score_spread":0.2831465048446524,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}